Organogenesis (ORGO) and Its Peers Head to Head Review

Organogenesis (NASDAQ:ORGO) is one of 846 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Organogenesis to related businesses based on the strength of its dividends, analyst recommendations, profitability, earnings, institutional ownership, risk and valuation.

Profitability

This table compares Organogenesis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organogenesis	-39.34%	-55.28%	-23.72%
Organogenesis Competitors	-12,285.98%	-196.04%	-30.61%

Analyst Recommendations

This is a summary of current ratings and target prices for Organogenesis and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1	2	0	0	1.67
Organogenesis Competitors	9904	15273	45596	1593	2.54

Organogenesis presently has a consensus price target of $4.33, indicating a potential upside of 363.36%. As a group, “Biotechnology” companies have a potential upside of 99.38%. Given Organogenesis’ higher possible upside, equities analysts clearly believe Organogenesis is more favorable than its peers.

Risk and Volatility

Organogenesis has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Organogenesis’ peers have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Institutional & Insider Ownership

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 18.8% of Organogenesis shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Organogenesis and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Organogenesis	$349.58 million	$37.03 million	-0.77
Organogenesis Competitors	$722.00 million	$11.43 million	-14.85

Organogenesis’ peers have higher revenue, but lower earnings than Organogenesis. Organogenesis is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Organogenesis beats its peers on 9 of the 13 factors compared.

Organogenesis Company Profile

Organogenesis Holdings Inc. is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue. Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.